Understanding the 'Durable Effect' Concept of B-cell Modulating Therapies
NCT06586177
·
clinicaltrials.gov ↗
RECRUITING
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
DRUG:
Anti-CD20 antibody
Sponsor
Heinrich-Heine University, Duesseldorf
Collaborators
[object Object]